Both claims are supported by credible scientific evidence. Peptides' role in anti-aging, longevity, and brain health is established through mechanistic studies (probiotic-derived peptides, bone cytokines, fungal peptides) and early clinical translation (NCT04390646 on GnRH and cognition). GLP-1, GIP, and dual GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) are backed by robust Phase 3 human trial data demonstrating metabolic and cardiovascular benefits, with active clinical development ongoing. The evidence tier ranges from preclinical (C. elegans, in-vitro) to large-scale human RCTs, providing a solid conceptual and clinical foundation for both claims.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
Peptide vibes #hormonehealth #functionalmedicine #womenshealth #perimenopause #wellnessbalanceyou #menopausesupport #hormonehealth #texaswellness #hormonebalance #
Video transcriptshow
Hey there, this is Charisse. I'm excited. I'm sitting here in Austin Airport getting ready to board. So, obviously here in Texas, it's 6.45. In Vegas, when I land, it'll be 8.30. So I'll be tired, but yet I'll still have plenty of time to do something before I start my conference tomorrow. So tomorrow is a pre-conference focus on hormones with an androgen as in testosterone DHEA connection. Also, …
Show full video transcript
we're going to be focusing on PCOS. That's a very near and dear part of my practice and mostly with my younger patients. We talk about fertility and what we can do in terms of improving their metabolic health. We're also going to talk about different kinds of hormonal testing and my very favorite case studies and panel discussion. And then Thursday, Friday, Saturday, Sunday, here is my schedule for my peptide certification. You're looking at labs. You're looking at telomere and markings of biological age. You're looking at brain health and peptides. You are looking at GLP-1s, GIPs, semiglutide, terzapatide. So that's very, very exciting. So it's really an anti-aging longevity focus. I will keep you guys posted about what I learn. Again, I'm pumped. I'm coming home late Sunday night, and I am grateful to my husband for taking care of the home front and allowing me to get all of this done. So just think of it this way. Everybody else is at the NFR and I'm busy studying.
Show lessClaim breakdown
2 claims“Peptides are involved in anti-aging and longevity, as well as brain health.”
Strong conceptual support across multiple evidence tiers. Peptides are documented regulators of aging and neurodegeneration: probiotic-derived quorum-sensing peptides (CSF) in Bacillus subtilis delayed neurodegeneration and restored lifespan in C. elegans AD models (PMID: 31884470, preclinical); bone-derived peptide cytokines (FGF23, OCN, LCN2) are recognized endocrine mediators linking skeletal health to longevity and brain function (PMID: 37402956, review of mechanistic pathways); and fungal-derived peptides (Ganoderma lucidum) antagonize beta-amyloid neurotoxicity in brain tissue models (PMID: 18083148, in-vitro mechanism). A Phase 2/3 human trial (NCT04390646) is actively recruiting to test pulsatile GnRH (a peptide hormone) on cognition in Down Syndrome, indicating clinical translation of peptide-brain health concepts.
“GLP-1s, GIPs, semaglutide, and tirzepatide are being discussed in the context of peptide certification, implying their therapeutic relevance.”
Strong clinical evidence across multiple tiers. GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) are well-established peptide therapeutics with extensive human Phase 3 trial data demonstrating metabolic, weight loss, and cardiovascular benefits (PMID: 36050763, Nauck & D'Alessio comprehensive review of SURPASS 1-5 trials; PMID: 39735270, GLP-1/GIP/GCGR agonists for metabolic dysfunction). Three active clinical trials on ClinicalTrials.gov (NCT07653412, NCT03987919 completed Phase 3, NCT06803888 Phase 4) confirm ongoing clinical development and real-world efficacy. Tirzepatide's dual GIP/GLP-1 mechanism showed superior HbA1c reduction (1.24–2.58%) and weight loss (5.4–11.7 kg) compared to semaglutide in human randomized controlled trials.
Supporting studies
- 1
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Cardiovascular diabetology · 2022·PMID 36050763
- 2
GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
World journal of gastroenterology · 2024·PMID 39735270
- 3
GLP-1-based medications: Mechanisms involved in obesity treatment
Medicina clinica · 2025·PMID 40466247
- 4
Incretin hormones and type 2 diabetes
Diabetologia · 2023·PMID 37430117
- 5
What is the pipeline for future medications for obesity?
International journal of obesity (2005) · 2025·PMID 38302593
- 6
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis
Metabolism: clinical and experimental · 2025·PMID 39719170
- 7
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Diabetes care · 2024·PMID 38687506
- 8
Tirzepatide: A Review in Type 2 Diabetes
Drugs · 2024·PMID 38388874
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error